ExonHit, InGen BioSciences deal

ExonHit will acquire in vitro diagnostic company InGen for €18 million ($23 million) in a cash and stock deal. The resulting company will be named Diaxonhit. ExonHit will pay €8 million ($10.2 million) in cash and issue €10 million ($12.8 million) in new ExonHit shares to InGen shareholders. ExonHit will finance the acquisition through a private placement of €4.4 million ($5.6 million) to institutional investors with the remaining balance covered by cash on hand. ...